Adare Pharma Solutions is a global technology-driven CDMO providing turnkey product development through commercial manufacturing expertise focused on oral dosage forms for the Pharmaceutical, Animal Health and OTC markets. Adare’s specialized technology platforms provide taste masking, controlled release, solubility enhancement and patient-centric dosing solutions. With a proven history in drug delivery, Adare has developed and manufactured more than 40 products sold by customers in more than 100 countries globally.

Strategic Quote

"Frazier Healthcare Partners and Thomas H. Lee saw that Adare was an asset with significant technical capability, deep customer relationships, and a strong vision to be a differentiated, technology-driven CDMO. We believe that under their leadership, Adare will achieve that vision and prove itself as an end-to-end CDMO partner to pharmaceutical companies.”

-Vivek Sharma, CEO, Adare Pharma Solutions

Corporate Video

Key Leadership

Vivek Sharma, Chief Executive Officer Vivek brings over 25 years of global operational experience in North America, Europe, and Asia. The last 15 years have been spent in the pharmaceutical industry, including contract manufacturing, critical care, and healthcare analytic segments. He was formerly CEO at Piramal Pharma Solutions and Decision Resources Group.

Mark Valentino, Chief Financial Officer Mark was previously Chief Financial Officer at PeroxyChem. Prior to PeroxyChem, Mark held various finance roles in both private and publicly owned global manufacturing and service-related companies. Mark holds a Bachelor of Science in Accounting from Seton Hall University, an MBA from Monmouth University and a master’s in taxation from Villanova University.

Matt Perry, Vice President, Operations & Chief Supply Chain Officer

Matt is responsible for leading all activities related to Operations, which include all Quality functions, Manufacturing, Supply Chain and Global Information Technology. Matt brings over 25 years of Operations experience and joins us from Atrium Innovations, a Nestle Health Science company, where he led the global supply chain and all manufacturing operations. Prior to Atrium Innovations, Matt spent nearly twenty years with Johnson & Johnson. Matt holds a Bachelor of Engineering degree from Stevens Institute of Technology in Hoboken, New Jersey.

Giovanni Ortenzi, Vice President, Pharmaceutical Development & Chief Technical Officer

Giovanni leads our global pharmaceutical development, technical services and operational excellence teams. He was previously Vice President, Quality at Adare leading quality assurance, quality control, clinical quality assurance and compliance teams. Prior to that, he led the quality teams at Aptalis Pharmaceutical Technologies. Giovanni held leading positions at Eurand, including Industrial Operations Director–Europe. He also formerly held quality and manufacturing positions with Bristol-Myers Squibb.

Giovanni holds degrees in Pharmaceutical Chemistry and Pharmacy from the University La Sapienza in Rome, Italy.

Daniel Belanger, Vice President, Human Resources

Daniel holds the position of Vice President, Human Resources. He previously served as the Global Human Resources Business Partner of Aptalis Pharmaceutical Technologies. Over the past 17 years, he held various leadership roles in human resources for Aptalis Pharma and Axcan Pharma.

Primary Products & Services

Adare’s Specialized Technologies:

The Parvulet ®Technology is a patient centric dosage solution that enables a solid powder or tablet to convert to a semi-solid in the presence of water within thirty seconds. The final dosage is easily administered, as a soft food like texture, ideal for pediatric and geriatric populations (including those with dysphagia).

AdvaTab® Orally Disintegrating Tablets (ODTs) incorporates coated or uncoated drug particles that are uniformly dispersed in a low-moisture, rapidly disintegrating matrix. Each ODT is formulated to achieve an acceptable taste and desired release profile. AdvaTab® technology is ideal for patients who have difficulty swallowing, pediatric, geriatric, and dysphagic patients. This technology can be combined with Microcaps® and Diffucaps® to create Immediate release or controlled release ODTs.

Diffucaps® Customized Release Technology has the flexibility to incorporate functional, release-controlling polymers or protective coatings onto drug-layered cores, granules, or crystals. This allows for easy adjustment of both dosage strength and dissolution profile to achieve the desired in vivo pharmacokinetic profile. Beads can have different release profiles, different active ingredients, or both—all in one product.

Microcaps® Taste Masking and Modified Release Technology achieves uniform and efficient coating of drug particles by coacervation (phase separation) to build polymeric membranes of varying porosity and thickness. The result is a free-flowing powder containing microencapsulated API (or API substrate) in a wide range of particle sizes. The Microcaps technology can be applied to multiple dosage forms for both immediate and modified-release profiles

MMTS TM Multi Mini Tablet System Customized Release Technology combines the simplicity of a tablet formulation with the flexibility of multiparticulate dosage forms with high drug-loading capability. Adare has developed Ultra Microtablets—a smaller standard of tablets targeting diameters in the range of 1.2 mm to even 1.0 mm. The small size facilitates the development of products that can offer multiple drugs or varying release profiles within a single capsule. The DIFFUTAB® technology is an effective solution for targeted drug delivery through customized and sustained release. The technology assists the development of high-dosage and sustained release products for once-daily administration. A matrix tablet is coated with functional polymers, followed by a blend of hydrophilic and hydrophobic polymers. Layered erosion and diffusion of the drug matrix tablet result in a controllable release.

Precision Particle Fabrication™ technology produces uniform microspheres and microcapsules with narrow size distribution and precise control over particle structure. The platform technology is flexible and customizable to accommodate a broad range of active ingredients, including small molecules, peptides, and proteins. The technology includes three platforms: Optimμm®, for oral delivery; StratμmTM, for injectable delivery; and Unisun®, for otic delivery.


1200 Lenox Drive, Suite 100 Lawrenceville, NJ 08648 609-450-1312